A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Publication | Open Access

DOI Full Paper Access

139

Citations

References

2010

Year

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes, Katalin Boér, Antoine Adenis, P. Escudero, Tae You Kim, G. Pover, Clive Morris, Jean-Yves Douillard

Investigational New Drugs

Phase IiGastrointestinal OncologyMedicinePharmacologyPathologyColorectal CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyMolecular OncologyCapecitabine Monotherapy